Evidence map›Paper›PMID 26274343›Full record

ArticleThe Journal of clinical endocrinology and metabolism2015

PTCSC3 Is Involved in Papillary Thyroid Carcinoma Development by Modulating S100A4 Gene Expression.

Jaroslaw Jendrzejewski, Andrew Thomas, Sandya Liyanarachchi, Andrew Eiterman, Jerneja Tomsic, Huiling He, Hanna S Radomska, Wei Li, Rebecca Nagy, Krzysztof Sworczak and 1 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of clinical endocrinology and metabolism, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 69 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Jaroslaw JendrzejewskiHuman Cancer Genetics Program, Comprehensive Cancer Center (J.J., A.T., S.L., A.E., J.T., H.H., H.S.R., W.L., R.N., A.d.l.C.), The Ohio State University, Columbus, Ohio, 43210; and Department of Endocrinology and Internal Medicine (J.J., K.S.), Medical University of Gdansk, Poland.
Andrew ThomasHuman Cancer Genetics Program, Comprehensive Cancer Center (J.J., A.T., S.L., A.E., J.T., H.H., H.S.R., W.L., R.N., A.d.l.C.), The Ohio State University, Columbus, Ohio, 43210; and Department of Endocrinology and Internal Medicine (J.J., K.S.), Medical University of Gdansk, Poland.
Sandya LiyanarachchiHuman Cancer Genetics Program, Comprehensive Cancer Center (J.J., A.T., S.L., A.E., J.T., H.H., H.S.R., W.L., R.N., A.d.l.C.), The Ohio State University, Columbus, Ohio, 43210; and Department of Endocrinology and Internal Medicine (J.J., K.S.), Medical University of Gdansk, Poland.
Andrew EitermanHuman Cancer Genetics Program, Comprehensive Cancer Center (J.J., A.T., S.L., A.E., J.T., H.H., H.S.R., W.L., R.N., A.d.l.C.), The Ohio State University, Columbus, Ohio, 43210; and Department of Endocrinology and Internal Medicine (J.J., K.S.), Medical University of Gdansk, Poland.
Jerneja TomsicHuman Cancer Genetics Program, Comprehensive Cancer Center (J.J., A.T., S.L., A.E., J.T., H.H., H.S.R., W.L., R.N., A.d.l.C.), The Ohio State University, Columbus, Ohio, 43210; and Department of Endocrinology and Internal Medicine (J.J., K.S.), Medical University of Gdansk, Poland.
Huiling HeHuman Cancer Genetics Program, Comprehensive Cancer Center (J.J., A.T., S.L., A.E., J.T., H.H., H.S.R., W.L., R.N., A.d.l.C.), The Ohio State University, Columbus, Ohio, 43210; and Department of Endocrinology and Internal Medicine (J.J., K.S.), Medical University of Gdansk, Poland.
Hanna S RadomskaHuman Cancer Genetics Program, Comprehensive Cancer Center (J.J., A.T., S.L., A.E., J.T., H.H., H.S.R., W.L., R.N., A.d.l.C.), The Ohio State University, Columbus, Ohio, 43210; and Department of Endocrinology and Internal Medicine (J.J., K.S.), Medical University of Gdansk, Poland.
Wei LiHuman Cancer Genetics Program, Comprehensive Cancer Center (J.J., A.T., S.L., A.E., J.T., H.H., H.S.R., W.L., R.N., A.d.l.C.), The Ohio State University, Columbus, Ohio, 43210; and Department of Endocrinology and Internal Medicine (J.J., K.S.), Medical University of Gdansk, Poland.
Rebecca NagyHuman Cancer Genetics Program, Comprehensive Cancer Center (J.J., A.T., S.L., A.E., J.T., H.H., H.S.R., W.L., R.N., A.d.l.C.), The Ohio State University, Columbus, Ohio, 43210; and Department of Endocrinology and Internal Medicine (J.J., K.S.), Medical University of Gdansk, Poland.
Krzysztof SworczakHuman Cancer Genetics Program, Comprehensive Cancer Center (J.J., A.T., S.L., A.E., J.T., H.H., H.S.R., W.L., R.N., A.d.l.C.), The Ohio State University, Columbus, Ohio, 43210; and Department of Endocrinology and Internal Medicine (J.J., K.S.), Medical University of Gdansk, Poland.
Albert de la ChapelleHuman Cancer Genetics Program, Comprehensive Cancer Center (J.J., A.T., S.L., A.E., J.T., H.H., H.S.R., W.L., R.N., A.d.l.C.), The Ohio State University, Columbus, Ohio, 43210; and Department of Endocrinology and Internal Medicine (J.J., K.S.), Medical University of Gdansk, Poland.
Cancer Genetics (United States) · USThe Ohio State University · USGdańsk Medical University · PL

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3M
The Ohio State University and MD Anderson Cancer Center Thyroid Cancer SPOREP50CA168505 · NCI · OHIO STATE UNIVERSITY · PI DE LA CHAPELLE, ALBERT · 2013 to 2017
$10.9M
NCI NIH HHS P30 CA016058NCI NIH HHS P30CA16058NCI NIH HHS P50 CA168505NCI NIH HHS P50CA168505
6 · The paper itself

Abstract

contextWe previously showed that a long noncoding RNA gene, PTCSC3, located close to the variant rs944289 that predisposes to papillary thyroid carcinoma (PTC) might target the S100A4 gene.

objectiveThe aim was to investigate the impact of PTCSC3 on S100A4 expression and its role in cancer development.

designS100A4 abundance was analyzed by quantitative PCR (qPCR) in unaffected and tumor tissue from n = 73 PTC patients. The expression of PTCSC3 and S100A4 was studied in BCPAP and TPC-1 cell lines with forced expression of PTCSC3 by qPCR. Expression of S100A4 target genes (VEGF and MMP-9) was studied in the BCPAP cell line with forced expression of PTCSC3 by qPCR, reverse transcriptase PCR, and Western blot. The impact of PTCSC3 on BCPAP motility and invasiveness was analyzed by the Transwell and Matrigel assays, respectively.

settingThis was a laboratory-based study using cells from clinical samples and thyroid cancer cell lines. MAIN OUTCOME AND MEASURE: We aimed to find evidence for a link between the expression of PTCSC3 and thyroid carcinogenesis.

resultsExpression data from PTC cell lines pinpointed S100A4 as the most significantly downregulated gene in the presence of PTCSC3. S100A4 was upregulated in tumor tissue (P = 9.33 × 10(-7)) while PTCSC3 was strongly downregulated (P = 2.2 × 10(-16)). S100A4 transcription was moderately correlated with PTCSC3 expression in unaffected thyroid tissue (r = 0.429, P = .0001), and strongly in unaffected tissue of patients with the risk allele of rs944289 (r = 0.685, P = 7.88 × 10(-5)). S100A4, VEGF, and MMP-9 were suppressed in the presence of PTCSC3 (P = .0051, P = .0090, and P =.0037, respectively). PTC cells expressing PTCSC3 showed reduction in motility and invasiveness (P = 4.52 × 10(-5) and P = 1.0 × 10(-4), respectively).

conclusionsPTCSC3 downregulates S100A4, leading to a reduction in cell motility and invasiveness. We propose that PTCSC3 impacts PTC predisposition and carcinogenesis through the S100A4 pathway.

Indexed as

CarcinogenesisCarcinoma, PapillaryCell Line, TumorCell ProliferationDown-RegulationGene Expression Regulation, NeoplasticGenetic Predisposition to DiseaseGenotypeHumansMatrix Metalloproteinase 9Neoplasm InvasivenessRNA, UntranslatedS100 Calcium-Binding Protein A4S100 ProteinsThyroid GlandThyroid NeoplasmsMatrix Metalloproteinase 9Ptcsc3 untranslated RNA, humanRNA, UntranslatedS100A4 protein, humanS100 Calcium-Binding Protein A4S100 ProteinsVascular Endothelial Growth Factor A

Identifiers

PMID26274343
PMCPMC4596031
OpenAlexW1912933938

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.